Who
Jeffrey Cerio
General Counsel
Company insider
Files Form 4 as: General Counsel, Korro Bio.
In numbers
- Trades disclosed
- 9
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $143K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 3 Sep 2024
- Last trade
- 15 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 17 Jul 2026 | KRRO Korro BioBiotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | KRRO Korro BioBiotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | KRRO Korro BioBiotechnology | SEC FORM 4 Sold | $72K6,609 at $10.83 | filing |
| 16 Jun 2026filed 17 Jun 2026 | KRRO Korro BioBiotechnology | SEC FORM 4 Sold | $72K6,609 at $10.83 | filing |
| 2 Feb 2026filed 3 Feb 2026 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 15 Dec 2025filed 16 Dec 2025 | KRRO Korro BioBiotechnology | SEC FORM 4 Code A | —41,902 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —29,000 at $0.00 | filing |
| 3 Sep 2024filed 3 Sep 2024 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
BioLineRx (NASDAQ:BLRX) and Korro Bio (NASDAQ:KRRO) Head to Head SurveyKRRO · dailypolitical.com · 14 Oct 2026Contrasting BioLineRx (NASDAQ:BLRX) & Korro Bio (NASDAQ:KRRO)KRRO · tickerreport.com · 14 Oct 2026Korro Bio Doses First Cohort In Phase 1/2 Study Of KRRO-121 For HyperammonemiaKRRO · rttnews.com · 7 Oct 2026
0 headlines in the last 90 days name Jeffrey Cerio; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.